$0.91
-0.11 (-10.67%)
Open$1.01
Previous Close$1.02
Day High$1.01
Day Low$0.91
52W High$3.07
52W Low$0.53
Volume—
Avg Volume3.23M
Market Cap219.86M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,257.3% upside
Current
$0.91
$0.91
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 90.30M | 178.19M | 160.29M |
| Net Income | -88,724,350 | 4.92M | 3.11M |
| Profit Margin | -98.3% | 2.8% | 1.9% |
| EBITDA | -92,624,961 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |